首页> 外文期刊>Alzheimer’s & dementia: the journal of the Alzheimer’s Association >The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
【24h】

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

机译:由阿尔茨海默氏病引起的痴呆症的诊断:美国老年痴呆症协会协会工作组对阿尔茨海默氏病诊断指南的建议。

获取原文
获取原文并翻译 | 示例
       

摘要

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
机译:美国国家老龄研究所和老年痴呆症协会负责一个工作组,其任务是修订1984年老年痴呆症(AD)痴呆症的标准。工作组试图确保修订后的标准具有足够的灵活性,以供普通医疗保健提供者使用,而无需进行神经心理学测试,先进的影像学检查和脑脊液测量,以及参与研究或临床试验研究的专门研究人员均应具备这些条件可用工具。我们提出了全因痴呆和AD痴呆的标准。我们从1984年的标准中保留了可能的AD痴呆症的一般框架。根据过去27年的经验,我们对诊断的临床标准进行了几次更改。我们还保留了可能的AD痴呆一词,但以一种比以前更加集中的方式对其进行了重新定义。生物标志物证据也被整合到诊断制剂中,用于可能和可能的AD痴呆,用于研究环境。 AD痴呆症的核心临床标准将继续是临床实践中诊断的基石,但是生物标志物的证据有望增强AD痴呆症诊断的病理生理特异性。验证AD痴呆的生物标志物诊断的工作还有很多。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号